Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Enterotoxigenic Escherichia coli-blood group A interactions intensify diarrheal severity.

Kumar P, Kuhlmann FM, Chakraborty S, Bourgeois AL, Foulke-Abel J, Tumala B, Vickers TJ, Sack DA, DeNearing B, Harro CD, Wright WS, Gildersleeve JC, Ciorba MA, Santhanam S, Porter CK, Gutierrez RL, Prouty MG, Riddle MS, Polino A, Sheikh A, Donowitz M, Fleckenstein JM.

J Clin Invest. 2019 Jul 1;129(7):2980. doi: 10.1172/JCI130874. Epub 2019 Jul 1. No abstract available.

2.

Hyperimmune bovine colostral anti-CS17 antibodies protect against enterotoxigenic Escherichia coli diarrhea in a randomized, doubled-blind, placebo-controlled human infection model.

Savarino SJ, McKenzie R, Tribble DR, Porter CK, O'Dowd A, Sincock SA, Poole ST, DeNearing B, Woods CM, Kim H, Grahek SL, Brinkley C, Crabb JH, Bourgeois AL.

J Infect Dis. 2019 Mar 21. pii: jiz135. doi: 10.1093/infdis/jiz135. [Epub ahead of print]

PMID:
30897198
3.

A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.

Bernstein DI, Pasetti MF, Brady R, Buskirk AD, Wahid R, Dickey M, Cohen M, Baughman H, El-Khorazaty J, Maier N, Sztein MB, Baqar S, Bourgeois AL.

Vaccine. 2019 Jan 21;37(4):602-611. doi: 10.1016/j.vaccine.2018.12.011. Epub 2018 Dec 15.

PMID:
30563789
4.

Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients.

Bouard L, Bodet-Milin C, Bailly C, Guillaume T, Peterlin P, Garnier A, Bourgeois AL, Mahé B, Dubruille V, Blin N, Touzeau C, Gastinne T, Lok A, Bonnet A, Béné MC, Gouill SL, Moreau P, Kraeber-Bodéré F, Chevallier P.

Biol Blood Marrow Transplant. 2019 May;25(5):906-911. doi: 10.1016/j.bbmt.2018.11.019. Epub 2018 Nov 24.

PMID:
30481598
5.

Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.

Akhtar M, Chowdhury MI, Bhuiyan TR, Kaim J, Ahmed T, Rafique TA, Khan A, Rahman SIA, Khanam F, Begum YA, Sharif MZ, Islam LN, Carlin N, Maier N, Fix A, Wierzba TF, Walker RI, Bourgeois AL, Svennerholm AM, Qadri F, Lundgren A.

Vaccine. 2018 Nov 22. pii: S0264-410X(18)31563-9. doi: 10.1016/j.vaccine.2018.11.040. [Epub ahead of print]

6.

Human Experimental Challenge With Enterotoxigenic Escherichia coli Elicits Immune Responses to Canonical and Novel Antigens Relevant to Vaccine Development.

Chakraborty S, Randall A, Vickers TJ, Molina D, Harro CD, DeNearing B, Brubaker J, Sack DA, Bourgeois AL, Felgner PL, Liang X, Mani S, Wenzel H, Townsend RR, Gilmore PE, Darsley MJ, Rasko DA, Fleckenstein JM.

J Infect Dis. 2018 Sep 22;218(9):1436-1446. doi: 10.1093/infdis/jiy312.

PMID:
29800314
7.

Enterotoxigenic Escherichia coli-blood group A interactions intensify diarrheal severity.

Kumar P, Kuhlmann FM, Chakraborty S, Bourgeois AL, Foulke-Abel J, Tumala B, Vickers TJ, Sack DA, DeNearing B, Harro CD, Wright WS, Gildersleeve JC, Ciorba MA, Santhanam S, Porter CK, Gutierrez RL, Prouty MG, Riddle MS, Polino A, Sheikh A, Donowitz M, Fleckenstein JM.

J Clin Invest. 2018 Aug 1;128(8):3298-3311. doi: 10.1172/JCI97659. Epub 2018 Jun 25. Erratum in: J Clin Invest. 2019 Jul 1;129(7):2980.

8.

Impact of lower challenge doses of enterotoxigenic Escherichia coli on clinical outcome, intestinal colonization and immune responses in adult volunteers.

Chakraborty S, Harro C, DeNearing B, Brubaker J, Connor S, Maier N, Dally L, Flores J, Bourgeois AL, Walker R, Sack DA.

PLoS Negl Trop Dis. 2018 Apr 27;12(4):e0006442. doi: 10.1371/journal.pntd.0006442. eCollection 2018 Apr.

9.

Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score.

Porter CK, Lynen A, Riddle MS, Talaat K, Sack D, Gutiérrez RL, McKenzie R, DeNearing B, Feijoo B, Kaminski RW, Taylor DN, Kirkpatrick BD, Bourgeois AL.

PLoS One. 2018 Mar 28;13(3):e0194325. doi: 10.1371/journal.pone.0194325. eCollection 2018.

10.

Vaccines against Shigella and enterotoxigenic Escherichia coli: A summary of the 2016 VASE Conference.

Walker RI, Wierzba TF, Mani S, Bourgeois AL.

Vaccine. 2017 Dec 14;35(49 Pt A):6775-6782. doi: 10.1016/j.vaccine.2017.09.045. Epub 2017 Oct 4.

11.

Prophylactic Efficacy of Hyperimmune Bovine Colostral Antiadhesin Antibodies Against Enterotoxigenic Escherichia coli Diarrhea: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial.

Savarino SJ, McKenzie R, Tribble DR, Porter CK, O'Dowd A, Cantrell JA, Sincock SA, Poole ST, DeNearing B, Woods CM, Kim H, Grahek SL, Brinkley C, Crabb JH, Bourgeois AL.

J Infect Dis. 2017 Jul 1;216(1):7-13. doi: 10.1093/infdis/jix144.

PMID:
28541500
12.

Status of vaccine research and development for enterotoxigenic Escherichia coli.

Bourgeois AL, Wierzba TF, Walker RI.

Vaccine. 2016 Jun 3;34(26):2880-2886. doi: 10.1016/j.vaccine.2016.02.076. Epub 2016 Mar 15.

13.

An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli.

Porter CK, Riddle MS, Alcala AN, Sack DA, Harro C, Chakraborty S, Gutierrez RL, Savarino SJ, Darsley M, McKenzie R, DeNearing B, Steinsland H, Tribble DR, Bourgeois AL.

PLoS One. 2016 Mar 3;11(3):e0149358. doi: 10.1371/journal.pone.0149358. eCollection 2016.

14.

Risk of hormonotherapy in transgender people: Literature review and data from the French Database of Pharmacovigilance.

Bourgeois AL, Auriche P, Palmaro A, Montastruc JL, Bagheri H.

Ann Endocrinol (Paris). 2016 Feb;77(1):14-21. doi: 10.1016/j.ando.2015.12.001. Epub 2016 Jan 29. Review.

PMID:
26830952
15.

Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407.

Chakraborty S, Harro C, DeNearing B, Ram M, Feller A, Cage A, Bauers N, Bourgeois AL, Walker R, Sack DA.

Clin Vaccine Immunol. 2015 Nov 18;23(1):55-64. doi: 10.1128/CVI.00617-15. Print 2016 Jan.

16.

Toxins and virulence factors of enterotoxigenic Escherichia coli associated with strains isolated from indigenous children and international visitors to a rural community in Guatemala.

Torres OR, González W, Lemus O, Pratdesaba RA, Matute JA, Wiklund G, Sack DA, Bourgeois AL, Svennerholm AM.

Epidemiol Infect. 2015 Jun;143(8):1662-71. doi: 10.1017/S0950268814002295. Epub 2014 Sep 19.

17.

Functionality of Varroa-resistant honey bees (Hymenoptera: Apidae) when used for western U.S. honey production and almond pollination.

Rinderer TE, Danka RG, Johnson S, Bourgeois AL, Frake AM, Villa JD, De Guzman LI, Harris JW.

J Econ Entomol. 2014 Apr;107(2):523-30.

PMID:
24772530
18.

Estimating diarrheal illness and deaths attributable to Shigellae and enterotoxigenic Escherichia coli among older children, adolescents, and adults in South Asia and Africa.

Lamberti LM, Bourgeois AL, Fischer Walker CL, Black RE, Sack D.

PLoS Negl Trop Dis. 2014 Feb 13;8(2):e2705. doi: 10.1371/journal.pntd.0002705. eCollection 2014 Feb. Review.

19.

Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.

Kaminski RW, Wu M, Turbyfill KR, Clarkson K, Tai B, Bourgeois AL, Van De Verg LL, Walker RI, Oaks EV.

Clin Vaccine Immunol. 2014 Mar;21(3):366-82. doi: 10.1128/CVI.00683-13. Epub 2014 Jan 8.

20.

Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli.

El-Kamary SS, Cohen MB, Bourgeois AL, Van De Verg L, Bauers N, Reymann M, Pasetti MF, Chen WH.

Clin Vaccine Immunol. 2013 Nov;20(11):1764-70. doi: 10.1128/CVI.00464-13. Epub 2013 Sep 18. Erratum in: Clin Vaccine Immunol. 2014 Apr;21(4):602.

21.

The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease.

Darsley MJ, Chakraborty S, DeNearing B, Sack DA, Feller A, Buchwaldt C, Bourgeois AL, Walker R, Harro CD.

Clin Vaccine Immunol. 2012 Dec;19(12):1921-31. doi: 10.1128/CVI.00364-12. Epub 2012 Oct 3.

22.

Functionality of Varroa-resistant honey bees (Hymenoptera: Apidae) when used in migratory beekeeping for crop pollination.

Danka RG, De Guzman LI, Rinderer TE, Sylvester HA, Wagener CM, Bourgeois AL, Harris JW, Villa JD.

J Econ Entomol. 2012 Apr;105(2):313-21.

PMID:
22606798
23.

A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults.

Harro C, Sack D, Bourgeois AL, Walker R, DeNearing B, Feller A, Chakraborty S, Buchwaldt C, Darsley MJ.

Clin Vaccine Immunol. 2011 Dec;18(12):2118-27. doi: 10.1128/CVI.05342-11. Epub 2011 Oct 12.

24.

Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens.

Feller AJ, McKenzie R, Taylor DN, Woods CC, Grahek SL, Islam D, Venkatesan MM, Hale TL, Bourgeois AL.

Vaccine. 2011 Nov 3;29(47):8487-9. doi: 10.1016/j.vaccine.2011.09.030. Epub 2011 Sep 20.

25.

Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines.

Harro C, Chakraborty S, Feller A, DeNearing B, Cage A, Ram M, Lundgren A, Svennerholm AM, Bourgeois AL, Walker RI, Sack DA.

Clin Vaccine Immunol. 2011 Oct;18(10):1719-27. doi: 10.1128/CVI.05194-11. Epub 2011 Aug 18.

26.

Volunteer challenge with enterotoxigenic Escherichia coli that express intestinal colonization factor fimbriae CS17 and CS19.

McKenzie R, Porter CK, Cantrell JA, Denearing B, O'Dowd A, Grahek SL, Sincock SA, Woods C, Sebeny P, Sack DA, Tribble DR, Bourgeois AL, Savarino SJ.

J Infect Dis. 2011 Jul 1;204(1):60-4. doi: 10.1093/infdis/jir220.

27.

Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and Mexico.

Koo HL, Ajami NJ, Jiang ZD, Neill FH, Atmar RL, Ericsson CD, Okhuysen PC, Taylor DN, Bourgeois AL, Steffen R, DuPont HL.

J Clin Microbiol. 2010 May;48(5):1673-6. doi: 10.1128/JCM.02072-09. Epub 2010 Mar 19.

28.

Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans.

Tribble DR, Baqar S, Scott DA, Oplinger ML, Trespalacios F, Rollins D, Walker RI, Clements JD, Walz S, Gibbs P, Burg EF 3rd, Moran AP, Applebee L, Bourgeois AL.

Infect Immun. 2010 Apr;78(4):1750-9. doi: 10.1128/IAI.01021-09. Epub 2010 Jan 19.

29.

Enterotoxigenic Escherichia coli multilocus sequence types in Guatemala and Mexico.

Nicklasson M, Klena J, Rodas C, Bourgeois AL, Torres O, Svennerholm AM, Sjoling A.

Emerg Infect Dis. 2010 Jan;16(1):143-6. doi: 10.3201/eid1601.090979.

30.

Genetic detection and quantification of Nosema apis and N. ceranae in the honey bee.

Bourgeois AL, Rinderer TE, Beaman LD, Danka RG.

J Invertebr Pathol. 2010 Jan;103(1):53-8. doi: 10.1016/j.jip.2009.10.009. Epub 2009 Oct 20.

PMID:
19850047
31.

Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis.

Gaston JS, Inman RD, Ryan ET, Venkatesan MM, Barry EM, Hale TL, Bourgeois AL, Walker RI.

Vaccine. 2009 Sep 4;27(40):5432-4. doi: 10.1016/j.vaccine.2009.06.107. Epub 2009 Jul 28.

PMID:
19643213
32.
33.

Enterotoxigenic Escherichia coli and diffusely adherent E. coli as likely causes of a proportion of pathogen-negative travelers' diarrhea--a PCR-based study.

Meraz IM, Jiang ZD, Ericsson CD, Bourgeois AL, Steffen R, Taylor DN, Hernandez N, DuPont HL.

J Travel Med. 2008 Nov-Dec;15(6):412-8. doi: 10.1111/j.1708-8305.2008.00249.x.

34.

Risk factors for antibiotic-resistant E. coli in children in a rural area.

Seidman JC, Anitha K P, Kanungo R, Bourgeois AL, Coles CL.

Epidemiol Infect. 2009 Jun;137(6):879-88. doi: 10.1017/S0950268808001519. Epub 2008 Nov 12.

35.

A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC.

McKenzie R, Darsley M, Thomas N, Randall R, Carpenter C, Forbes E, Finucane M, Sack RB, Hall E, Bourgeois AL.

Vaccine. 2008 Aug 26;26(36):4731-9. doi: 10.1016/j.vaccine.2008.06.064. Epub 2008 Jul 9.

PMID:
18602960
36.

Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.

Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, Okhuysen PC, Guerrero NH, Martinez-Sandoval FG, Meléndez-Romero JH, Jiang ZD, Asturias EJ, Halpern J, Torres OR, Hoffman AS, Villar CP, Kassem RN, Flyer DC, Andersen BH, Kazempour K, Breisch SA, Glenn GM.

Lancet. 2008 Jun 14;371(9629):2019-25. doi: 10.1016/S0140-6736(08)60839-9.

PMID:
18554712
37.

Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate.

McKenzie R, Venkatesan MM, Wolf MK, Islam D, Grahek S, Jones AM, Bloom A, Taylor DN, Hale TL, Bourgeois AL.

Vaccine. 2008 Jun 19;26(26):3291-6. doi: 10.1016/j.vaccine.2008.03.079. Epub 2008 Apr 16.

PMID:
18468742
38.

Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.

Taylor DN, McKenzie R, Durbin A, Carpenter C, Haake R, Bourgeois AL.

Antimicrob Agents Chemother. 2008 Mar;52(3):1179-81. Epub 2007 Dec 17.

39.

Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico.

Sack DA, Shimko J, Torres O, Bourgeois AL, Francia DS, Gustafsson B, Kärnell A, Nyquist I, Svennerholm AM.

Vaccine. 2007 May 30;25(22):4392-400. Epub 2007 Apr 4.

PMID:
17448578
40.

Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.

McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, Glenn GM.

Vaccine. 2007 May 4;25(18):3684-91. Epub 2007 Jan 23.

PMID:
17313998
41.

Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum.

Glenn GM, Villar CP, Flyer DC, Bourgeois AL, McKenzie R, Lavker RM, Frech SA.

Infect Immun. 2007 May;75(5):2163-70. Epub 2007 Jan 29.

42.

Enterotoxigenic Escherichia coli with STh and STp genotypes is associated with diarrhea both in children in areas of endemicity and in travelers.

Bölin I, Wiklund G, Qadri F, Torres O, Bourgeois AL, Savarino S, Svennerholm AM.

J Clin Microbiol. 2006 Nov;44(11):3872-7. Epub 2006 Aug 30.

43.

A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea.

Taylor DN, Bourgeois AL, Ericsson CD, Steffen R, Jiang ZD, Halpern J, Haake R, Dupont HL.

Am J Trop Med Hyg. 2006 Jun;74(6):1060-6.

PMID:
16760520
44.

Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge.

Taylor DN, McKenzie R, Durbin A, Carpenter C, Atzinger CB, Haake R, Bourgeois AL.

Clin Infect Dis. 2006 May 1;42(9):1283-8. Epub 2006 Mar 22.

PMID:
16586388
45.

Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults.

McKenzie R, Bourgeois AL, Engstrom F, Hall E, Chang HS, Gomes JG, Kyle JL, Cassels F, Turner AK, Randall R, Darsley M, Lee C, Bedford P, Shimko J, Sack DA.

Infect Immun. 2006 Feb;74(2):994-1000.

46.

Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers.

Carpenter CM, Hall ER, Randall R, McKenzie R, Cassels F, Diaz N, Thomas N, Bedford P, Darsley M, Gewert C, Howard C, Sack RB, Sack DA, Chang HS, Gomes G, Bourgeois AL.

Vaccine. 2006 May 1;24(18):3709-18. Epub 2005 Jul 26.

PMID:
16153753
47.

Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.

Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J, Bentley M, Makin J, Chatfield S, Hindle Z, Fidler C, Robinson BE, Ventrone CH, Bansal N, Carpenter CM, Kutzko D, Hamlet S, LaPointe C, Taylor DN.

Vaccine. 2006 Jan 12;24(2):116-23. Epub 2005 Aug 18.

PMID:
16140433
48.

Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.

McKenzie R, Walker RI, Nabors GS, Van De Verg LL, Carpenter C, Gomes G, Forbes E, Tian JH, Yang HH, Pace JL, Jackson WJ, Bourgeois AL.

Vaccine. 2006 May 1;24(18):3735-45. Epub 2005 Jul 21.

PMID:
16095766
49.

Prevention of disease in ferrets fed an inactivated whole cell Campylobacter jejuni vaccine.

Burr DH, Rollins D, Lee LH, Pattarini DL, Walz SS, Tian JH, Pace JL, Bourgeois AL, Walker RI.

Vaccine. 2005 Jul 29;23(34):4315-21.

PMID:
16005742
50.

Prevalence of norovirus among visitors from the United States to Mexico and Guatemala who experience traveler's diarrhea.

Chapin AR, Carpenter CM, Dudley WC, Gibson LC, Pratdesaba R, Torres O, Sanchez D, Belkind-Gerson J, Nyquist I, Kärnell A, Gustafsson B, Halpern JL, Bourgeois AL, Schwab KJ.

J Clin Microbiol. 2005 Mar;43(3):1112-7.

Supplemental Content

Loading ...
Support Center